Create an agile regulatory framework and maintain a strong incentives' system, says EFPIA in EU roadmap comments

30 April 2021

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has filed its response to the European Union (EU) roadmap/IIA on the Evaluation and revision of the general pharmaceutical legislation.

This roadmap contains proposed priorities for legislative change to equip the regulatory framework to respond quickly to the needs of patients across Europe.

"The evaluation of the general pharmaceutical legislation is a once-in-a-lifetime opportunity to make Europe a world leader in medical innovation"EFPIA director general Nathalie Moll said: “The evaluation of the general pharmaceutical legislation is a once-in-a-lifetime opportunity to make Europe a world leader in medical innovation and build back better from the COVID-19 crisis. To achieve these goals, the focus must be on creating an agile regulatory framework and maintaining a strong incentives’ system that embrace and encourage advances in science, technology and medicines.”

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK